Clinical Focus ›› 2024, Vol. 39 ›› Issue (1): 38-42.doi: 10.3969/j.issn.1004-583X.2024.01.006
Previous Articles Next Articles
Huang Saihu1, Long Zhongjie2, Dong Xingqiang1, Meng Xiangying1, Wu Shuiyan1, Bai Zhenjiang1()
Received:
2023-11-25
Online:
2024-01-20
Published:
2024-03-22
CLC Number:
Huang Saihu, Long Zhongjie, Dong Xingqiang, Meng Xiangying, Wu Shuiyan, Bai Zhenjiang. Pathogen and clinical characteristics of children with hematologic neoplasms complicated with sepsis[J]. Clinical Focus, 2024, 39(1): 38-42.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.01.006
病原菌种类 | 株数 (株) | 占所有检出病原菌 的百分比(%) | |
---|---|---|---|
革兰阴性杆菌(68株) | 铜绿假单胞菌 | 16 | 10.26 |
肺炎克雷伯杆菌 | 16 | 10.26 | |
大肠埃希菌 | 15 | 9.62 | |
阴沟肠杆菌 | 4 | 2.56 | |
嗜麦芽窄食单胞菌 | 3 | 1.92 | |
鲍曼不动杆菌 | 2 | 1.28 | |
其他 | 12 | 7.69 | |
小计 | 68 | 43.59 | |
革兰阳性球菌(87株) | 表皮葡萄球菌 | 35 | 22.44 |
人葡萄球菌 | 18 | 11.54 | |
缓症链球菌 | 10 | 6.41 | |
肺炎链球菌 | 7 | 4.49 | |
金黄色葡萄球菌 | 3 | 1.92 | |
屎肠球菌 | 3 | 1.92 | |
其他 | 11 | 7.05 | |
小计 | 87 | 55.77 | |
真菌(1株) | 近平滑念珠菌 | 1 | 0.64 |
Tab.1 Pathogen distribution in children with sepsis
病原菌种类 | 株数 (株) | 占所有检出病原菌 的百分比(%) | |
---|---|---|---|
革兰阴性杆菌(68株) | 铜绿假单胞菌 | 16 | 10.26 |
肺炎克雷伯杆菌 | 16 | 10.26 | |
大肠埃希菌 | 15 | 9.62 | |
阴沟肠杆菌 | 4 | 2.56 | |
嗜麦芽窄食单胞菌 | 3 | 1.92 | |
鲍曼不动杆菌 | 2 | 1.28 | |
其他 | 12 | 7.69 | |
小计 | 68 | 43.59 | |
革兰阳性球菌(87株) | 表皮葡萄球菌 | 35 | 22.44 |
人葡萄球菌 | 18 | 11.54 | |
缓症链球菌 | 10 | 6.41 | |
肺炎链球菌 | 7 | 4.49 | |
金黄色葡萄球菌 | 3 | 1.92 | |
屎肠球菌 | 3 | 1.92 | |
其他 | 11 | 7.05 | |
小计 | 87 | 55.77 | |
真菌(1株) | 近平滑念珠菌 | 1 | 0.64 |
药物 | 铜绿假单胞菌 ( | 肺炎克雷伯杆菌 ( | 大肠埃希菌 ( |
---|---|---|---|
氨苄西林 | 0 | 12.50 | 0 |
庆大霉素 | 93.75 | 62.50 | 86.67 |
妥布霉素 | 100.00 | 62.50 | 80.00 |
环丙沙星 | 75.00 | 25.00 | 33.33 |
左旋氧氟沙星 | 87.50 | 31.25 | 66.67 |
复方新诺明 | 0 | 0 | 20.00 |
氨苄西林/舒巴坦 | 0 | 25.00 | 66.67 |
哌拉西林他唑巴坦 | 87.50 | 93.75 | 93.33 |
头孢替坦 | 0 | 93.75 | 93.33 |
头孢他啶 | 75.00 | 93.75 | 86.67 |
头孢曲松 | 0 | 62.50 | 73.33 |
头孢吡肟 | 93.75 | 87.50 | 93.33 |
亚胺培南 | 50.00 | 93.75 | 93.33 |
氨曲南 | 56.25 | 75.00 | 80.00 |
哌拉西拉 | 81.25 | - | - |
头孢哌酮舒巴坦 | 68.75 | 93.75 | 93.33 |
美洛培南 | 56.25 | 93.75 | 93.33 |
丁胺卡那霉素 | 100.00 | 87.50 | 100.00 |
产超广谱β内酰胺酶 | - | 31.25 | 20.00 |
Tab.2 Susceptibility rates of the top three Gram-negative bacteria (%)
药物 | 铜绿假单胞菌 ( | 肺炎克雷伯杆菌 ( | 大肠埃希菌 ( |
---|---|---|---|
氨苄西林 | 0 | 12.50 | 0 |
庆大霉素 | 93.75 | 62.50 | 86.67 |
妥布霉素 | 100.00 | 62.50 | 80.00 |
环丙沙星 | 75.00 | 25.00 | 33.33 |
左旋氧氟沙星 | 87.50 | 31.25 | 66.67 |
复方新诺明 | 0 | 0 | 20.00 |
氨苄西林/舒巴坦 | 0 | 25.00 | 66.67 |
哌拉西林他唑巴坦 | 87.50 | 93.75 | 93.33 |
头孢替坦 | 0 | 93.75 | 93.33 |
头孢他啶 | 75.00 | 93.75 | 86.67 |
头孢曲松 | 0 | 62.50 | 73.33 |
头孢吡肟 | 93.75 | 87.50 | 93.33 |
亚胺培南 | 50.00 | 93.75 | 93.33 |
氨曲南 | 56.25 | 75.00 | 80.00 |
哌拉西拉 | 81.25 | - | - |
头孢哌酮舒巴坦 | 68.75 | 93.75 | 93.33 |
美洛培南 | 56.25 | 93.75 | 93.33 |
丁胺卡那霉素 | 100.00 | 87.50 | 100.00 |
产超广谱β内酰胺酶 | - | 31.25 | 20.00 |
药物 | 表皮葡萄球菌 ( | 人葡萄球菌 ( | 缓症链球菌 ( |
---|---|---|---|
氯霉素 | 62.86 | 44.44 | 70.00 |
利奈唑胺 | 100.00 | 100.00 | 100.00 |
万古霉素 | 100.00 | 100.00 | 100.00 |
四环素 | 85.71 | 61.11 | 70.00 |
替加环素 | 100.00 | 100.00 | - |
利福平 | 100.00 | 100.00 | - |
复方新诺明 | 40.00 | 22.22 | - |
青霉素G | 0 | 0 | 30.00 |
苯唑西林 | 0 | 5.55 | - |
庆大霉素 | 74.29 | 100.00 | - |
环丙沙星 | 65.71 | 77.78 | - |
左氧氟沙星 | 65.71 | 88.89 | 100.00 |
莫西沙星 | 65.71 | 77.78 | - |
红霉素 | 25.71 | 16.67 | 20.00 |
克林霉素 | 77.14 | 100.00 | 70.00 |
头孢噻肟 | - | - | 70.00 |
奎诺普汀/达福普汀 | 100.00 | 100.00 | 80.00 |
Tab.3 Susceptibility rates of the top three Gram-positive bacteria (%)
药物 | 表皮葡萄球菌 ( | 人葡萄球菌 ( | 缓症链球菌 ( |
---|---|---|---|
氯霉素 | 62.86 | 44.44 | 70.00 |
利奈唑胺 | 100.00 | 100.00 | 100.00 |
万古霉素 | 100.00 | 100.00 | 100.00 |
四环素 | 85.71 | 61.11 | 70.00 |
替加环素 | 100.00 | 100.00 | - |
利福平 | 100.00 | 100.00 | - |
复方新诺明 | 40.00 | 22.22 | - |
青霉素G | 0 | 0 | 30.00 |
苯唑西林 | 0 | 5.55 | - |
庆大霉素 | 74.29 | 100.00 | - |
环丙沙星 | 65.71 | 77.78 | - |
左氧氟沙星 | 65.71 | 88.89 | 100.00 |
莫西沙星 | 65.71 | 77.78 | - |
红霉素 | 25.71 | 16.67 | 20.00 |
克林霉素 | 77.14 | 100.00 | 70.00 |
头孢噻肟 | - | - | 70.00 |
奎诺普汀/达福普汀 | 100.00 | 100.00 | 80.00 |
[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
doi: 10.3322/caac.v68.1 URL |
[2] |
Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: An updated systematic analysis[J]. Lancet, 2015, 385(9965): 371-379.
doi: 10.1016/S0140-6736(14)60383-4 URL |
[3] |
Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: The sepsis prevalence, outcomes, and therapies study[J]. Am J Respir Crit Care Med, 2015, 191(10) : 1147-1157.
doi: 10.1164/rccm.201412-2323OC URL |
[4] | Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children[J]. Intensive Care Med, 2020, 21(2):e52-e106. |
[5] |
Maia RR, Wunsch FV. Infection and childhood leukemia: Review of evidence[J]. Rev Saude Publica, 2013, 47(6):1172-1185.
doi: 10.1590/S0034-89102013000901172 URL |
[6] |
Klein K, Hasle H, Abrahamsson J, et al. Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlin-Frankfurt-Munster(I-BFM)study group[J]. Br J Haematol, 2018, 183(1):87-95.
doi: 10.1111/bjh.2018.183.issue-1 URL |
[7] |
Pole JD, Gibson P, Ethier MC, et al. Evaluation of treatment-related mortality among paediatric cancer deaths: A population based analysis[J]. British journal of cancer, 2017, 116(4): 540-545.
doi: 10.1038/bjc.2016.443 pmid: 28095399 |
[8] | Alexander S, Pole JD, Gibson P, et al. Classification of treatment-related mortality in children with cancer: A systematic assessment[J]. The Lancet Oncology, 2015, 16(16): e604-e610. |
[9] |
Loeffen EAH, Knops RRG, Boerhof J, et al. Treatment-related mortality in children with cancer: Prevalence and risk factors[J]. Eur J Cancer, 2019, 121: 113-122.
doi: S0959-8049(19)30468-X pmid: 31569066 |
[10] |
Ehrlich BS, McNeil MJ, Pham LTD, et al. Treatment-related mortality in children with cancer in low-income and middle-income countries: A systematic review and meta-analysis[J]. The Lancet Oncology, 2023, 24(9):967-977.
doi: 10.1016/S1470-2045(23)00318-2 URL |
[11] | 陈芬, 安美玉, 姚彤, 等. 15例血液肿瘤患儿化疗后感染合并急性呼吸窘迫综合征回顾性分析[J]. 中国小儿血液与肿瘤杂志, 2020, (1):24-27. |
[12] |
Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients[J]. J Infect, 2014, 68(4):321-331.
doi: 10.1016/j.jinf.2013.12.006 pmid: 24370562 |
[13] |
Feld Ronald. Bloodstream infections in cancer patients with febrile neutropenia[J]. Int J Antimicrob Agents, 2008, 32:S30-S33.
doi: 10.1016/j.ijantimicag.2008.06.017 URL |
[14] | 王坚敏, 汤静燕, 张蓓, 等. 儿童恶性肿瘤合并感染病原菌调查[J]. 中华医院感染学杂志, 2009, (9):354-357. |
[15] |
Murray C, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis[J]. The Lancet, 2022, 399(10325):629-655.
doi: 10.1016/S0140-6736(21)02724-0 URL |
[16] |
Averbuch D, Avaky C, Harit M, et al. Non-fermentative gram-negative rods bacteremia in children with cancer: A 14-year single-center experience[J]. Infection, 2017, 45(3):327-334.
doi: 10.1007/s15010-017-0988-1 pmid: 28205160 |
[17] |
Limmathurotsakul D, Dunachie S, Fukuda K, et al. Improving the estimation of the global burden of antimicrobial resistant infections[J]. Lancet Infect Dis, 2019, 19: e392-e398.
doi: 10.1016/S1473-3099(19)30276-2 |
[18] |
Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon[J]. Pathog Glob Health, 2015, 109: 309-318.
doi: 10.1179/2047773215Y.0000000030 pmid: 26343252 |
[19] | Thaden JT, Park LP, Maskarinec SA, et al. Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by pseudomonas aeruginosa compared to other bacteria[J]. Antimicrob Agents Chemother, 2017, 61(6):e02671-16. |
[20] | 熊玲玲, 马琼, 袁有华, 等. 铜绿假单胞菌血流感染57例的死亡危险因素分析[J]. 中国感染与化疗杂志, 2021, 21(3):154-257. |
[21] |
Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies[J]. Clin Infect Dis, 2014, 58:1274-1283.
doi: 10.1093/cid/ciu052 pmid: 24463280 |
[22] | 姚佳峰, 蔡思雨, 李楠, 等. 2016-2017年单中心血液肿瘤患儿感染病原菌分布的临床特点分析[J]. 北京医学, 2018, 40(4):301-304. |
[23] | 王晓晖, 钱素云. PICU中央导管相关血流感染患儿的临床特点分析:单中心回顾性研究[J]. 中国小儿急救医学, 2019, 26(7):492-496. |
[24] | 王文超, 王颖雯, 康琼芳, 等. 儿科中心静脉通路装置发生导管相关性血流感染危险因素的系统评价[J]. 2020, 15(4):261-268. |
[25] |
王丹, 张娜, 邵静波, 等. 血液肿瘤患儿中心静脉导管相关血流感染的危险因素分析[J]. 中国感染与化疗杂志, 2022, 22(1):1-7.
doi: 10.16718/j.1009-7708.2022.01.001 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||